Drug discovery is adapting to novel technologies such as data science, informatics, and
artificial intelligence (AI) to accelerate effective treatment development while reducing costs …

Optimisation of compound pharmacokinetics (PK) is an integral part of drug discovery and
development. Animal in vivo PK data as well as human and animal in vitro systems are …

As pharmaceutical development moves from early-stage in vitro experimentation to later in
vivo and subsequent clinical trials, data and knowledge are acquired across multiple time …

While poor translatability of preclinical efficacy models can be responsible for clinical phase
II failures, misdefinition of the optimal PK properties required to achieve therapeutic efficacy …

In pharmaceutical science, multi‐step drug product development processes generate an
enormous amount of datasets each day as a part of chemistry, pre‐clinical and clinical …

Accurate prediction of a new compound's pharmacokinetic (PK) profile is pivotal for the
success of drug discovery programs. An initial assessment of PK in preclinical species and …

In recent years, virtual drug study, as an emerging research strategy, has become
increasingly important in guiding and promoting new drug research and development …

Small molecule drug discovery involves extensive evaluation of potencies, molecular
physicochemical properties, and pharmacokinetic (PK) properties related to absorption …

A successful drug needs to combine several properties including high potency and good
pharmacokinetic (PK) properties to sustain efficacious plasma concentration over time. To …

Abstract Development of antibodies often begins with the assessment and optimizing of their
physicochemical properties, and their efficient engagement to the target of interest …